February 6, 2007 – ImClone decided to develop its own VEGFr-2 inhibitor, rather than to partner with UCB on another VEGFr-2 inhibitor; Synta priced its IPO at $10 per share, a 33% drop; CytRx will determine the maximum safe dosage of arimoclomal for ALS and use the dosage in a Phase IIb double-blind trial; Genta will appeal the non-approvable ruling for Genasense; Avigen reported that AV411 (ibudilast) was well tolerated in Phase I trial; BioCryst said oncology drug Fodosine was given Orphan Drug status in Europe for cutaneous T-cell lymphoma; ViaCell will stop development of its umbilical cord blood transplant therapy, CB001; and GenVec published data showing it delivered the math1 gene to inner ear cells of mice, re-generating inner ear hair cells and restoring a sense of balance. The Centient Biotech 200™ was 4 points lower at 4050, a decline of .10%. More details...
